Michael Savona

Beverly and George Rawlings Director of Hematology Research and Professor of Medicine and Cancer Biology

Vanderbilt University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Michael Savona is the Beverly and George Rawlings Director of Hematology Research and Professor of Medicine and Cancer Biology at Vanderbilt University. His research primarily focuses on hematological malignancies, including myelodysplastic syndromes and acute myeloid leukemia, as evidenced by his recent publications involving gene classifiers and clonal hematopoiesis dynamics. He is dedicated to advancing treatment strategies and understanding clonal evolution in blood cancers.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Alice Mims

Ohio State University

UNITED STATES

View details

Melissa A. Fischer

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

View details

Adam Mead

University of Oxford

UNITED KINGDOM

View details

Alexander Bick

Assistant Professor

Vanderbilt University

UNITED STATES

View details

Scott Guelcher

Professor

Vanderbilt University

UNITED STATES

View details

Yaomin Xu

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Savona

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies

Methylation sequencing enhances interpretation of clonal hematopoiesis dynamics

Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk

Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia

Publisher Correction: Germline risk of clonal haematopoiesis

Germline risk of clonal haematopoiesis

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Establishing specific response criteria for MDS/MPN - Getting closer to reality?

The evolving role of next generation sequencing in myelodysplastic syndromes

Collaborators (6)

Alice Mims

Melissa A. Fischer

Adam Mead

Alexander Bick

Scott Guelcher

Yaomin Xu

Make your next move.